Investigational drug · Phase 3
Hydronidone
Also called: F351
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Liver Fibrosis, Chronic Hepatitis B With Hepatic Fibrosis, Liver Fibrosis in Chronic Hepatitis B.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
2 still active
All registered trials
17
Any phase or sponsor naming "Hydronidone"
First trial start
2023
Aug 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Hydronidone", any sponsor or status.
Conditions studied
As listed on its trial records.
- Liver Fibrosis
- Chronic Hepatitis B With Hepatic Fibrosis
- Liver Fibrosis in Chronic Hepatitis B
- Chronic Hepatitis B-related Liver Fibrosis
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Hydronidone" as an intervention, largest first.
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.Pivotal-lookingRecruiting
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07412236 · 1,208 participants (planned) · Start Mar 23, 2026 · Primary completion Dec 30, 2028
Drug: Hydronidone (270mg); Hydronidone (Placebo Group) · For: Liver Fibrosis; Liver Fibrosis in Chronic Hepatitis B
Sites: Shanghai, China
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07364448 · 411 participants · Start Mar 12, 2026 · Primary completion Jun 22, 2026
Drug: Hydronidone capsules · For: Chronic Hepatitis B With Hepatic Fibrosis
Sites: Jilin City, China
- A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisPivotal-lookingCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07343778 · 337 participants · Start Mar 16, 2026 · Primary completion Jul 28, 2026
Drug: Hydronidone Capsules · For: Chronic Hepatitis B With Hepatic Fibrosis
Sites: Zhengzhou, China
- Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.Pivotal-lookingCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT05115942 · 248 participants · Start Dec 30, 2021 · Primary completion Oct 22, 2024
Drug: Hydronidone capsules; The placebo capsules · For: Liver Fibrosis
Sites: Bengbu, China; Hefei, China; Beijing, China · 44 sites in all
- Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver FibrosisPivotal-lookingRecruiting
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT05905172 · 248 participants (planned) · Start Aug 12, 2023 · Primary completion Jun 20, 2028
Drug: Hydronidone capsules; The placebo capsules · For: Liver Fibrosis
Sites: Beijing, China; Shanghai, China; Bengbu, China · 23 sites in all
- A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic HepatitisPivotal-lookingCompleted
Shanghai Genomics, Inc.Industry
NCT02499562 · 168 participants · Start Jun 25, 2015 · Primary completion Nov 20, 2020
Drug: Hydronidone; Placebo and 1 more · For: Hepatitis B, Chronic
Sites: Shanghai, China; Beijing, China
- The Phase Ⅰd Clinical Trial of Hydronidone CapsulesPivotal-lookingCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07262346 · 138 participants · Start Dec 24, 2025 · Primary completion May 28, 2026
Drug: Hydronidone capsules; Placebo capsules · For: Liver Fibrosis
Sites: Wuhan, China
- A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver FibrosisCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07417553 · 67 participants · Start Apr 15, 2026 · Primary completion Jul 27, 2026
Drug: Hydronidone capsules · For: Chronic Hepatitis B-related Liver Fibrosis
Sites: Chongqing, China
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07295873 · 64 participants · Start Mar 15, 2026 · Primary completion May 29, 2026
Drug: Entecavir; Tenofovir Disoproxil Fumarate(TDF) and 2 more · For: Chronic Hepatitis B Liver Fibrosis; DDI (Drug-Drug Interaction)
Sites: Beijing, China
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07262333 · 56 participants (planned) · Start Dec 25, 2025 · Primary completion Dec 1, 2026
Drug: Hydronidone capsules · For: Renal Insufficiency Chronic
Sites: Hubei, China
Newest research
PubMed records naming it or its code names, newest first.
- TGF-β-Targeting Platinum(IV) Prodrugs Remodel Tumor Microenvironment of Pancreatic Cancer via Antifibrotic and Immunomodulatory Effects.
Li Z, Liu XM, Wang XY, et al. · J Med Chem 2026
- Application of Multilineage Human Liver Organoids in Disease Modelling, Drug Testing and Genetic Intervention.
Ge Q, Zhang Q, Chen R, et al. · Liver Int 2026
- Exploring mitochondrial genetic features in intervertebral disc degeneration through multi-omics integration analyses.
Xu F, Wang C, Sun M, et al. · J Gerontol A Biol Sci Med Sci 2026
- Hydronidone Mitigates Pulmonary Fibrosis by Regulating the TGF-β/Smad2/3 Axis in in Vitro and in Vivo Models.
Andugulapati SB, Kambhampati V, Kumar B H · ACS Pharmacol Transl Sci 2025
- Hydronidone Alleviates Metabolic Dysfunction-Associated Fatty Liver Disease by Inhibiting CD36 Expression.
Luo X, Lu JY, Shen ZY, et al. · FASEB J 2025
- A gain-of-function mutation in ATP6V0A4 drives primary distal renal tubular alkalosis with enhanced V-ATPase activity.
Peng SQ, Wu QQ, Wang WY, et al. · J Clin Invest 2025
Also in development for Liver Fibrosis
- AZD2389Phase 22 trials
AstraZeneca · Liver Fibrosis, Hepatic Cirrhosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.